Navigation Links
Perrigo Confirms Filing for Generic Version of Men's Rogaine(R) Foam
Date:10/13/2009

ALLEGAN, Mich., Oct. 13 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of Men's Rogaine(®) Foam.

Men's Rogaine(®) (Minoxidil) topical aerosol foam, 5%, is a topical hair re-growth treatment indicated for the re-growth of hair on top of the scalp, and has estimated sales at retail of approximately $52 million annually.

Perrigo filed its ANDA for Minoxidil topical aerosol foam, 5%, containing a paragraph IV certification with the U.S. Food & Drug Administration and notified Johnson & Johnson, the New Drug Application holder for Rogaine(®) Foam, and Stiefel Research Australia Pty. Ltd., the listed patent owner, of its filing. On October 9, 2009, Stiefel Research Australia Pty. Ltd. filed suit alleging patent infringement in the United States District Court for the District of Delaware to prevent Perrigo from proceeding with the commercialization of this product. This action formally initiates the process under the Hatch-Waxman Act.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of how our ongoing focus on innovation and consistently bringing new products to market saves consumers money. Over the past 15 years Perrigo products have saved consumers over an estimated $10 billion compared to the national brand."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manuf
'/>"/>

SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
9. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
10. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
11. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015 Pepperl+Fuchs, a world leader ... Corporation, a leading provider of HART protocol devices. ... further extend its integrated solutions offerings and strengthen ... "We are pleased to add the MACTek ... Jim Bolin , Pepperl+Fuchs, executive vice president ...
(Date:8/31/2015)... , Aug. 31, 2015  Ascendant Solutions, Inc. ... today announced that its Healthcare subsidiary, Dougherty,s Holdings, has ... on the downtown square of Springtown, Texas ... than 35 years, this community-based pharmacy has provided retail ... of Springtown . The ...
(Date:8/31/2015)... 2015  Daktari Diagnostics today announced a collaboration with Merck, ... and Canada , to develop Daktari,s ... up to $8.5 million over the next 3.5 years, will ... regulatory approval of Daktari,s HCV test. The ... can detect low levels of virus directly in a single ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 2Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus 3
... grounds, direct programming is superior,to cloning as a ... Nov. 20 Two major scientific,papers published this ... way to,generate patient-matched human pluripotent stem cells without ... or human or animal eggs.,Research groups in Wisconsin ...
... 20 The following statement,was released today by ... the Elizabeth Glaser Pediatric AIDS Foundation:, "Four ... Relief,(PEPFAR) began funding treatment and prevention, today,s report ... remains a devastating worldwide,pandemic, we are beginning to ...
Cached Medicine Technology:Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 2Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo 3New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need 2
(Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and voice ... There are over 100 different types of arthritis. One of the most popular is ... to shed light on this important topic. , Anyone who is nearing their golden ...
(Date:9/1/2015)... ... September 01, 2015 , ... Specialty Technical Publishers ... International Audit Protocol Consortium (IAPC) EHS audit protocol for the European Union. Leading ... of their EHS regulatory obligations and rapidly collect, share, archive, and export audit ...
(Date:8/31/2015)... ... 01, 2015 , ... AthleticTraining.com, provider of CEUs for athletic ... new premium on-demand video Evidence Based Practice courses that meet ... must complete 50 CEUs before December 31, 2015, which must include at least ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... released their latest predictive use case focused on helping hospital perform under the ... this program, hospital payments are adjusted based on performance across four domains related ...
(Date:8/31/2015)... Oaks, CA (PRWEB) , ... August 31, 2015 ... ... recently been updated to include a wealth of information for specific translation services ... has great expertise and an incredible track record of successful work. , ITC ...
Breaking Medicine News(10 mins):Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 2Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 3Health News:Specialty Technical Publishers (STP) and Specialty Technical Consultants(STC) Publish Environmental, Health & Safety (EHS) Audit Protocol for the European Union 4Health News:Evidence Based Practice Courses: CEUs For Athletic Trainers Just Released 2Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3
... Md., Nov. 29 ,Micromet, Inc. (Nasdaq: MITI ) ... ongoing Phase 1 clinical trial of MT103 in patients ... the 2007 Annual,Meeting of the American Society of Hematology ... as MEDI-538, is a recombinant T-cell,engaging antibody, or BiTE(R) ...
... Such as Tenet and Kaiser, SUNNYVALE, ... announced it signed a group purchasing contract ... serving more than 20,000 acute care,hospitals, ambulatory ... throughout the United States. Under the terms ...
... Release Following Extension of Service Offering ... CEVA Third Quarter 2007 Results, HOOFDDORP, The ... Interim Financial Statements today. These,statements include the following highlights:, - ... - EBITDA increased to EUR86.9 million from EUR(4.3) million in ...
... HILLS, Calif., Nov. 29 CalbaTech, Inc.,(OTC ... company,( http://www.CalbaTech.com ) concentrating on the collection ... future therapeutic uses and providing,products and platforms ... to academic institutions, is pleased to announced ...
... New Report from the American Legacy Foundation(R) Finds ... 29 America,s Medicaid,system could spend nearly $10 ... who smoke, quit. A new study released today ... prevention and,cessation programs could cut Medicaid costs by ...
... the U.S. is caused by a form of bacteria, ... It typically begins with a bulls-eye skin rash, ... If diagnosed early, Lyme can be treated successfully ... Nearly 60 percent of patients who do not ...
Cached Medicine News:Health News:Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients 2Health News:Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients 3Health News:Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients 4Health News:Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients 5Health News:Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkin's Lymphoma Patients 6Health News:Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA 2Health News:Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA 3Health News:Cepheid and Broadlane Sign Group Purchasing Contract for GeneXpert(R) Systems and Xpert(TM) Molecular Diagnostic Tests, Including Xpert MRSA 4Health News:CEVA Group Plc Reports Quarter 3, 2007 Results 2Health News:CEVA Group Plc Reports Quarter 3, 2007 Results 3Health News:CEVA Group Plc Reports Quarter 3, 2007 Results 4Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 3Health News:Smokers Cost Medicaid System Nearly $10 Billion 2Health News:Smokers Cost Medicaid System Nearly $10 Billion 3Health News:Antibody responses in patients with Lyme arthritis 2Health News:Antibody responses in patients with Lyme arthritis 3
Alcon offers medical grade perfluoropropane (C3F8) intraocular gases for ophthalmological use....
Round knurled handle. Overall length 130 mm....
Optimum C/D/S Solution is a sterile cleaning, disinfecting, and storage solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and hard contact lenses....
5 inch (12.7 cm), 2 x 5 mm blade....
Medicine Products: